(ICL) ICL Israel Chemicals - Overview
Sector: Basic Materials | Industry: Agricultural Inputs | Exchange: NYSE (USA) | Market Cap: 8.338m USD | Total Return: 3.4% in 12m
Avg Turnover: 7.32M
EPS Trend: -85.2%
Qual. Beats: 0
Rev. Trend: -60.0%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Supp Ema8, Confidence
ICL Group Ltd is a global specialty minerals and chemicals company headquartered in Israel. The firm operates across four primary segments: Industrial Products, Potash, Phosphate Solutions, and Growing Solutions. Its business model leverages mineral assets to produce bromine-based compounds, potash, and phosphate-based fertilizers and food additives. The company serves a diverse range of end-markets, including agriculture, electronics, energy storage, and pharmaceuticals.
The company utilizes a vertically integrated model, extracting bromine from the byproduct of its potash production process to enhance cost efficiency. As a major player in the global fertilizer industry, ICL is subject to the cyclical nature of commodity prices, though its specialty chemical segments provide a degree of margin stability compared to pure-play commodity producers. Further analysis of these segment margins is available on ValueRay.
- Global potash price fluctuations directly impact core segment revenue and margins
- Dead Sea bromine production costs influenced by Israeli government royalty negotiations
- Global agricultural demand for specialty fertilizers drives Growing Solutions segment growth
- Geopolitical instability in the Middle East poses significant supply chain disruption risks
- Expansion into LFP battery materials diversifies revenue beyond traditional agricultural cycles
| Net Income: 261.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -2.62 > 1.0 |
| NWC/Revenue: 16.41% < 20% (prev 17.94%; Δ -1.53% < -1%) |
| CFO/TA 0.08 > 3% & CFO 1.06b > Net Income 261.0m |
| Net Debt (2.82b) to EBITDA (1.35b): 2.09 < 3 |
| Current Ratio: 1.38 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.29b) vs 12m ago -0.02% < -2% |
| Gross Margin: 30.40% > 18% (prev 0.33%; Δ 3.01k% > 0.5%) |
| Asset Turnover: 59.99% > 50% (prev 58.79%; Δ 1.20% > 0%) |
| Interest Coverage Ratio: 2.45 > 6 (EBITDA TTM 1.35b / Interest Expense TTM 297.0m) |
| A: 0.09 (Total Current Assets 4.45b - Total Current Liabilities 3.23b) / Total Assets 13.0b |
| B: 0.45 (Retained Earnings 5.83b / Total Assets 13.0b) |
| C: 0.06 (EBIT TTM 727.0m / Avg Total Assets 12.3b) |
| D: 0.91 (Book Value of Equity 6.07b / Total Liabilities 6.68b) |
| Altman-Z'' = 3.42 = A |
| DSRI: 0.86 (Receivables 1.65b/1.77b, Revenue 7.41b/6.87b) |
| GMI: 1.08 (GM 30.40% / 32.87%) |
| AQI: 1.00 (AQ_t 0.11 / AQ_t-1 0.11) |
| SGI: 1.08 (Revenue 7.41b / 6.87b) |
| TATA: -0.06 (NI 261.0m - CFO 1.06b) / TA 13.0b) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of May 30, 2026, the stock is trading at USD 6.64 with a total of 1,669,257 shares traded.
Over the past week, the price has changed by +2.63%,
over one month by +24.58%,
over three months by +39.56% and
over the past year by +3.44%.
ICL Israel Chemicals has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold ICL.
- StrongBuy: 0
- Buy: 0
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 6.4 | -4.4% |
P/E Trailing = 30.7619
P/E Forward = 55.5556
P/S = 1.1254
P/B = 1.3791
P/EG = 9.44
Revenue TTM = 7.41b USD
EBIT TTM = 727.0m USD
EBITDA TTM = 1.35b USD
Long Term Debt = 2.22b USD (from longTermDebt, last quarter)
Short Term Debt = 926.0m USD (from shortTermDebt, last quarter)
Debt = 3.40b USD (from shortLongTermDebtTotal, last quarter) + Leases 255.0m
Net Debt = 2.82b USD (calculated: Debt 3.40b - CCE 581.0m)
Enterprise Value = 11.2b USD (8.34b + Debt 3.40b - CCE 581.0m)
Interest Coverage Ratio = 2.45 (Ebit TTM 727.0m / Interest Expense TTM 297.0m)
EV/FCF = 42.13x (Enterprise Value 11.2b / FCF TTM 265.0m)
FCF Yield = 2.37% (FCF TTM 265.0m / Enterprise Value 11.2b)
FCF Margin = 3.58% (FCF TTM 265.0m / Revenue TTM 7.41b)
Net Margin = 3.52% (Net Income TTM 261.0m / Revenue TTM 7.41b)
Gross Margin = 30.40% ((Revenue TTM 7.41b - Cost of Revenue TTM 5.16b) / Revenue TTM)
Gross Margin QoQ = 30.94% (prev 27.51%)
Tobins Q-Ratio = 0.86 (Enterprise Value 11.2b / Total Assets 13.0b)
Interest Expense / Debt = 8.72% (Interest Expense 297.0m / Debt 3.40b)
Taxrate = 27.46% (53.0m / 193.0m)
NOPAT = 527.4m (EBIT 727.0m * (1 - 27.46%))
Current Ratio = 1.38 (Total Current Assets 4.45b / Total Current Liabilities 3.23b)
Debt / Equity = 0.56 (Debt 3.40b / totalStockholderEquity, last quarter 6.05b)
Debt / EBITDA = 2.09 (Net Debt 2.82b / EBITDA 1.35b)
Debt / FCF = 10.66 (Net Debt 2.82b / FCF TTM 265.0m)
Total Stockholder Equity = 6.04b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.11% (Net Income 261.0m / Total Assets 13.0b)
RoE = 4.32% (Net Income TTM 261.0m / Total Stockholder Equity 6.04b)
RoCE = 8.79% (EBIT 727.0m / Capital Employed (Equity 6.04b + L.T.Debt 2.22b))
RoIC = 4.95% (NOPAT 527.4m / Invested Capital 10.7b)
WACC = 7.42% (E(8.34b)/V(11.7b) * Re(7.86%) + D(3.40b)/V(11.7b) * Rd(8.72%) * (1-Tc(0.27)))
Discount Rate = 7.86% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 37.78 | Cagr: 0.00%
[DCF] Terminal Value 73.10% ; FCFF base≈376.9m ; Y1≈330.5m ; Y5≈267.1m
[DCF] Fair Price = 1.13 (EV 4.29b - Net Debt 2.82b = Equity 1.46b / Shares 1.29b; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -85.24 | EPS CAGR: -37.50% | SUE: 0.0 | # QB: 0
Revenue Correlation: -60.00 | Revenue CAGR: -4.38% | SUE: 2.12 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.10 | Chg30d=+10.00% | Revisions=+20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.11 | Chg30d=+5.77% | Revisions=-20% | Analysts=4
EPS current Year (2026-12-31): EPS=0.41 | Chg30d=+6.83% | Revisions=+33% | GrowthEPS=+14.2% | GrowthRev=+9.7%
EPS next Year (2027-12-31): EPS=0.45 | Chg30d=+5.36% | Revisions=+0% | GrowthEPS=+10.0% | GrowthRev=-0.1%
[Analyst] Revisions Ratio: +33%